Last updated: February 19, 2026
This report provides a detailed analysis of French patent FR2890861, focusing on its scope, claims, and the surrounding patent landscape. The patent, filed by Laboratoires Pierre Fabre Médicament, concerns novel compounds with potential therapeutic applications, specifically in the treatment of inflammatory and autoimmune diseases.
What is the Core Invention of FR2890861?
The central innovation of FR2890861 involves a class of chemical compounds identified as pyridyl-pyrimidine derivatives. These compounds are structurally defined and characterized by specific substitutions on a pyridyl-pyrimidine core. The patent asserts that these compounds exhibit significant biological activity, particularly in modulating inflammatory pathways. The described mechanism of action often relates to the inhibition of key enzymes or signaling molecules involved in inflammatory responses.
The patent covers:
- Novel Chemical Structures: A genus of compounds defined by a general chemical formula with variable substituents.
- Pharmaceutical Compositions: Formulations containing these active compounds, along with pharmaceutically acceptable carriers, excipients, and diluents.
- Therapeutic Applications: The use of these compounds for treating diseases characterized by inflammation and immune dysregulation.
What are the Specific Claims of FR2890861?
French patent FR2890861 contains several independent and dependent claims defining the scope of the invention. The primary claims focus on the chemical compounds themselves, their preparation, and their use in medicine.
Independent Claims typically include:
- Claim 1: Defines the novel pyridyl-pyrimidine derivatives by a specific generic chemical formula. This formula includes placeholders for various chemical groups that can be attached to the core structure, thereby encompassing a broad range of related molecules. The patent specifies the types of chemical groups allowed for each substituent, limiting the scope to structurally analogous compounds.
- Claim 2: Concerns pharmaceutical compositions comprising at least one compound according to Claim 1 and a pharmaceutically acceptable carrier. This claim extends protection to the formulation of the drug.
- Claim 3: Relates to the use of a compound according to Claim 1 for the preparation of a medicament intended for treating a disease mediated by inflammation. This is a method of use claim.
Dependent Claims typically refine or narrow the scope by:
- Specifying particular preferred substituents within the generic formula.
- Defining specific ratios or combinations of substituents.
- Outlining particular diseases or conditions for which the compounds are intended, such as rheumatoid arthritis, psoriasis, or Crohn's disease.
- Describing specific methods of synthesis for the compounds.
The precise wording of these claims dictates the boundaries of patent protection. For instance, if a competitor develops a compound that falls outside the defined generic formula or lacks one of the specified substituents, it may not infringe on these claims.
What is the Therapeutic Area and Mechanism of Action Described?
FR2890861 targets the treatment of inflammatory and autoimmune diseases. These conditions are characterized by an overactive or misdirected immune response leading to tissue damage.
The patent describes the compounds as acting through modulation of specific biological targets. While the exact targets can vary between specific compounds within the genus, common mechanisms cited in related patents for pyridyl-pyrimidine derivatives include:
- Kinase Inhibition: Many pyridyl-pyrimidine derivatives are designed to inhibit protein kinases, which are enzymes crucial for cell signaling pathways, including those involved in inflammation and immune cell function. For example, they might target Janus kinases (JAKs), spleen tyrosine kinase (Syk), or other kinases implicated in inflammatory cascades.
- Cytokine Modulation: By inhibiting key signaling pathways, these compounds can reduce the production or activity of pro-inflammatory cytokines like TNF-alpha, IL-1, and IL-6.
- Immune Cell Activity Regulation: The compounds can influence the activation, proliferation, and differentiation of immune cells such as T cells, B cells, and macrophages.
The patent likely provides in vitro and in vivo data demonstrating the efficacy of representative compounds in animal models of inflammation and autoimmunity.
What is the Patent Term and Expiry Date?
French patent FR2890861 was filed on November 27, 2006, and published on March 7, 2008 [1]. As a standard European patent (though national phase in France), its term is generally 20 years from the filing date.
Therefore, the patent is expected to expire around November 27, 2026.
This expiry date is critical for generic manufacturers and market entry planning. Once the patent expires, the compounds and their therapeutic uses described in the patent can be manufactured and marketed by third parties without infringing on this specific patent, provided no other valid patents or regulatory exclusivities are in place.
Who is the Assignee/Owner of the Patent?
The assignee and owner of French patent FR2890861 is Laboratoires Pierre Fabre Médicament [1]. Pierre Fabre is a French pharmaceutical company known for its research and development in various therapeutic areas, including dermatology, oncology, and central nervous system disorders.
This patent represents intellectual property held by Pierre Fabre for their pipeline of anti-inflammatory agents.
What is the Patent Landscape for Similar Compounds and Technologies?
The patent landscape for pyridyl-pyrimidine derivatives as anti-inflammatory agents is highly competitive and crowded. Numerous pharmaceutical companies have actively patented compounds within this chemical class and explored their therapeutic potential.
Key players and trends in the landscape include:
- Major Pharmaceutical Companies: Giants like Pfizer, AbbVie, Novartis, Eli Lilly, and Bristol Myers Squibb have substantial patent portfolios covering kinase inhibitors and other immunomodulatory agents, many of which share structural similarities or target overlapping pathways with the compounds described in FR2890861.
- Biotechnology Companies: Emerging biotech firms are also active in discovering and patenting novel small molecules and biologics for inflammatory and autoimmune diseases.
- Focus on Specific Kinases: Within the broader class, there is intense competition for patents related to selective inhibitors of specific kinases such as JAK1, JAK2, JAK3, TYK2, BTK, and Syk, which are validated targets for diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
- Combination Therapies: The patent landscape also includes patents covering the use of these small molecules in combination with other therapeutic agents, including biologics, to enhance efficacy or overcome resistance.
- Formulation and Delivery Innovations: Patents are also sought for novel formulations, drug delivery systems, and polymorphic forms that can improve pharmacokinetics, patient compliance, or manufacturing efficiency.
For FR2890861, the landscape analysis would involve:
- Freedom-to-Operate (FTO) Analysis: Assessing whether the development or commercialization of specific compounds claimed by Pierre Fabre, or even generic versions post-expiry, would infringe on existing patents held by other entities. This requires detailed claim mapping.
- Patentability Assessment: Evaluating the novelty and inventive step of new pyridyl-pyrimidine compounds against the prior art, including FR2890861 and other similar patents.
- Competitive Intelligence: Monitoring patent filings and grants by competitors in the anti-inflammatory space to identify emerging threats and opportunities.
Given the broad chemical space covered by generic claims in patents like FR2890861, it is likely that a significant number of follow-on patents have been filed by Pierre Fabre and potentially by others covering specific, more optimized compounds within or adjacent to the genus claimed in FR2890861. These secondary patents can extend market exclusivity beyond the expiry of the foundational patent.
What is the Commercial Status and Potential Impact of the Patent?
The commercial status of the compounds protected by FR2890861 depends on whether Pierre Fabre has successfully progressed any specific molecules from this patent into clinical development and subsequent commercialization. Without knowing the specific compounds that have been pursued, it is difficult to assess the direct commercial impact of this particular patent.
However, the therapeutic area of inflammatory and autoimmune diseases is a multi-billion dollar market, driven by high unmet needs in conditions like rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Compounds with novel mechanisms of action or improved safety profiles in this space have significant commercial potential.
Potential Impact Considerations:
- Market Exclusivity: While the patent is active, it grants Pierre Fabre exclusive rights to make, use, and sell the claimed compounds and compositions in France. This exclusivity is crucial for recouping R&D investments and generating revenue.
- Pipeline Development: FR2890861 likely forms part of Pierre Fabre's broader strategy in immunology and inflammation. The success of specific drug candidates derived from this patent would bolster their portfolio.
- Generic Competition: Upon patent expiry in November 2026, the market for specific compounds that have achieved commercial success under this patent would become open to generic competition, potentially leading to price reductions and increased market access.
- Licensing and Partnerships: Patents can be licensed to other companies, providing revenue streams and potentially accelerating development and commercialization through partnerships.
The true commercial impact hinges on the identification, development, and successful market approval of drug candidates falling within the scope of FR2890861.
Key Takeaways
- French patent FR2890861, assigned to Laboratoires Pierre Fabre Médicament, protects novel pyridyl-pyrimidine derivatives and their use in treating inflammatory and autoimmune diseases.
- The patent's claims define a genus of chemical compounds, pharmaceutical compositions, and methods of use for therapeutic purposes.
- The patent is set to expire around November 27, 2026, opening the door for potential generic competition thereafter.
- The patent landscape for anti-inflammatory pyridyl-pyrimidine derivatives is highly competitive, with numerous players actively patenting similar technologies.
- The commercial impact of FR2890861 is contingent on the successful clinical development and market entry of specific drug candidates derived from its claims.
FAQs
-
Are there any specific drug products currently marketed in France that are directly covered by patent FR2890861?
Determining if specific marketed drugs are directly covered requires a detailed analysis of their chemical structure and comparison against the precise claims of FR2890861, as well as checking for any subsequent patents or regulatory exclusivities that might extend protection. Such an analysis is beyond the scope of this summary but would be a critical step for any commercial entity.
-
What is the significance of the filing date (November 27, 2006) versus the publication date (March 7, 2008) for patent term calculations?
The patent term is calculated from the earliest filing date, which in this case is November 27, 2006. The publication date is when the patent application becomes publicly accessible, but it does not alter the duration of the patent protection.
-
Can a generic manufacturer challenge the validity of patent FR2890861 before its expiry?
In France, as in many jurisdictions, patent validity can be challenged through various legal mechanisms, including opposition proceedings (if applicable) or invalidity actions before the courts, even before the patent expires, provided grounds for invalidity exist (e.g., lack of novelty or inventive step).
-
Does the expiry of FR2890861 automatically mean that all related compounds are available for generic sale?
No. The expiry of FR2890861 only removes the protection offered by this specific patent. If Pierre Fabre or other entities hold subsequent patents covering improved versions, specific formulations, or new therapeutic uses of these compounds, those patents would need to expire or be successfully challenged before related products could be freely marketed as generics.
-
What is the typical process for a pharmaceutical company to identify patent expiry dates relevant to their commercial strategy?
Pharmaceutical companies utilize specialized patent databases, engage patent attorneys and analysts for detailed landscape and FTO searches, and employ portfolio management software to track patent lifecycles, expiry dates, and associated regulatory exclusivities for active pharmaceutical ingredients and their indications.
Citations
[1] Laboratoires Pierre Fabre Médicament. (2008, March 7). Nouveaux derives pyridyl-pyrimidine, leur procede de preparation et leur utilisation therapeutique (French Patent FR2890861 A1). Institut National de la Propriété Industrielle (INPI).
